Successful Treatment of Cutaneous Langerhans Cell Histiocytosis with Thalidomide

Sander, C; Kaatz, Martin; Elsner, P.

doi:10.1159/000076491

Cited by 29 publications

(26 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thalidomide of 200 mg daily successfully treated cutaneous Langerhans cell histiocytosis in 38-year-old male [7].…”

Section: Discussionmentioning

confidence: 98%

“…Thalidomide has shown beneficial effect in kaposi's sarcoma in HIV patients and in Human herpes virus-8-associated kaposi sarcoma following HSCT [6]. Thalidomide also exerts an antiproliferate effect against histiocytes [7]. In vitro, thalidomide inhibits TNF-a production by human monocytes and exerts an antiangiogenic effect by inhibiting vascular endothelial growth factor inhibition, basic-fibroblast growth factor, and IL-6 [4,5].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant

et al. 2007

View full text Add to dashboard Cite

Histiocytic sarcoma (HS) is a rare neoplasm of uncertain etiology. Most recently, the diagnostic criteria for this entity have been revised with inclusion of diagnostic modalities such as immunohistochemical and cytogentic techniques. HS tends to have an aggressive clinical course and presents with systemic symptoms of fever, weight loss, adenopathy, hepatosplenomegly, rash, and pancytopenia. Thalidomide is a promising agent that may exert a therapeutic benefit in HS. We report a case of a 48‐year‐old female with HS who presented with fever, weight loss, fatigue, generalized anasarca, and pancytopenia. She underwent multi‐agent chemotherapy followed by matched unrelated hematopoietic stem cell transplant. Her disease recurred and thalidomide therapy was started, with her overall disease burden significantly reduced as measured radiographically. Am. J. Hematol. 82:932–933, 2007. © 2007 Wiley‐Liss, Inc.

show abstract

“…Thalidomide of 200 mg daily successfully treated cutaneous Langerhans cell histiocytosis in 38-year-old male [7].…”

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Originally, thalidomide was recognized for its role in the treatment of erythema nodosum leprosum; however, thalidomide’s effectiveness is now well documented in a variety of diseases including aphthous stomatitis, discoid lupus erythematosus, actinic prurigo, Behçet’s disease, prurigo nodularis, cutaneous Langerhans cell histiocytosis, vulvar ulcerations associated with Crohn’s disease and HIV-associated dermatological conditions[ 30, 34, 35]. …”

Section: Discussionmentioning

confidence: 99%

Scleromyxedema, a Positive Effect with Thalidomide

Jacob

Fien²,

Kerdel³

2006

Dermatology

View full text Add to dashboard Cite

Scleromyxedema is a rare dermatological disorder marked by widespread symmetric 2- to 3-mm, firm, waxy, closely spaced papules involving the hands, forearms, face, neck, upper trunk and thighs. The most common extracutaneous manifestation of scleromyxedema is a benign plasma cell dyscrasia. Treatment of scleromyxedema is limited by the lack of long-term results, toxicity and significant adverse side effects. We report a severe case of scleromyxedema who had marked improvement when treated with thalidomide.

show abstract

“…This led to the evaluation of thalidomide in the treatment of several cancers [1]. Thalidomide has recently been used in the management of several inflammatory skin diseases including scleromyxedema, cutaneous Langerhans cell histiocytosis, sarcoidosis or discoid lupus erythematosus [2, 3]. Several studies have suggested its interest for treating AIDS-related KS, but only anecdotal reports are available in non-HIV-related KS.…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Analysis of Thalidomide Therapy in Non-HIV-Related Kaposi’s Sarcoma

M’barek

Fardet²,

Mebazâa³

et al. 2007

Dermatology

View full text Add to dashboard Cite

Background: Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies. Several studies have suggested its interest for treating AIDS-related Kaposi’s sarcoma. Objectives: This study aimed to assess the efficacy and toxicity of thalidomide, an antiangiogenic agent, for the treatment of non-HIV-related Kaposi’s sarcoma. Methods: Eleven patients were included in this retrospective study conducted in the Department of Dermatology of Saint Louis, Paris, between 2000 and 2003. Among them, 2 were immunosuppressed (1 renal transplant recipient and 1 patient with microscopic polyangiitis treated by oral steroids) with stable immunosuppressive regimens during the past 6 months. The median daily thalidomide dosage was 100 mg and the median duration of drug treatment was 16 weeks. Results: Three patients achieved a partial response and 4 had a stable disease. Although no grade 3 or 4 was observed, 3 (27%) out of 11 patients prematurely discontinued thalidomide because of grade 1 sensory neuropathy (paresthesia) and vertigo. Conclusions: Our results show a true although modest interest of thalidomide in non-HIV-related Kaposi’s sarcoma and prompt us to evaluate less toxic thalidomide analogues for this indication.

show abstract

Successful Treatment of Cutaneous Langerhans Cell Histiocytosis with Thalidomide

Cited by 29 publications

References 11 publications

Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant

Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant

Scleromyxedema, a Positive Effect with Thalidomide

A Retrospective Analysis of Thalidomide Therapy in Non-HIV-Related Kaposi’s Sarcoma

Contact Info

Product

Resources

About